-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: stats
Indices, IPOs, Approvals – YTD Update Aug 14th, 2012
We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed out a modest size IPO class, and delivered double digit novel FDA approvals. 1. Indices. The Nasdaq Biotech Index (NBI) is up 27% Year to Date (YTD) as of last Friday. It was up nearly 20% by the end of the 1st quarter, consolidated during the 2nd quarter, and has participated in the summer rally to tack on another 7%. Here Read More >
Partnering Milestones
In case you couldn’t tell, we’re really excited about the BIO Business Forum this year. As mentioned in an earlier post, we opened BIO One-on-One Partnering earlier than expected to accommodate the level of interest we were seeing. And we’re pleased to see that that interest has not been slowing down. How much so? We have over 2,300 business development professionals – from around the world – already registered. We’re up to 3,000+ number of Read More >
BIO Asia partnering is heating up!
Less than a week to go until the 7th Annual BIO Asia International Partnering Conference and it is clear that we are on pace to beat the number of total partnering meetings done from last year. Check out the little snippet from Google analytics to the right. This past Monday represented the highest day of activity within the system to date! In 2008, we had a total of 693 partnering meetings scheduled at the conference Read More >
1 in 4 Biotechs Above 100% – Waterfall Chart YTD
Year to date, 27% of biotech stocks have doubled in price. 65% are in positive territory in 2009, a strong contrast to the YTD data last year:
The Rise and Fall of Undervaluation
If “price to cash” is a usable metric for fair value of a risky biotech (i.e. valuation of a biotech vs what its cash balance is at the bank), then the cheap times are long gone. Back at the end of 2008 we had a record 24% of biotechs trading below cash. Investors were making the assumption that the previous reported cash balance was already being spent and additions to the balance were in jeopardy. Read More >
